Cerecor Inc (NASDAQ:CERC) major shareholder Armistice Capital Master Fund bought 2,200,000 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were bought at an average price of $3.05 per share, with a total value of $6,710,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Friday, August 30th, Armistice Capital Master Fund purchased 41,764 shares of Cerecor stock. The stock was bought at an average price of $3.22 per share, for a total transaction of $134,480.08.
  • On Monday, August 19th, Armistice Capital Master Fund purchased 12,184 shares of Cerecor stock. The stock was bought at an average cost of $3.46 per share, with a total value of $42,156.64.
  • On Wednesday, August 14th, Armistice Capital Master Fund purchased 100,000 shares of Cerecor stock. The stock was bought at an average cost of $3.33 per share, with a total value of $333,000.00.

Shares of NASDAQ CERC opened at $3.59 on Thursday. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.74 and a quick ratio of 0.71. Cerecor Inc has a 12 month low of $2.71 and a 12 month high of $7.65. The stock has a 50-day moving average price of $3.49 and a two-hundred day moving average price of $4.89.

A number of equities research analysts have issued reports on the stock. HC Wainwright set a $11.00 price objective on shares of Cerecor and gave the stock a “buy” rating in a research note on Wednesday, August 21st. Maxim Group set a $10.00 price target on shares of Cerecor and gave the stock a “buy” rating in a research report on Friday, August 9th. TheStreet lowered shares of Cerecor from a “c-” rating to a “d+” rating in a research report on Wednesday, May 29th. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $8.00 price objective on shares of Cerecor in a research note on Tuesday, July 2nd. Finally, ValuEngine upgraded shares of Cerecor from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $9.67.

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Cerecor by 56.5% during the 2nd quarter. Vanguard Group Inc. now owns 678,000 shares of the company’s stock worth $3,689,000 after purchasing an additional 244,657 shares in the last quarter. BlackRock Inc. lifted its stake in Cerecor by 4,046.6% in the 2nd quarter. BlackRock Inc. now owns 1,205,533 shares of the company’s stock valued at $6,559,000 after purchasing an additional 1,176,460 shares during the last quarter. Northern Trust Corp boosted its position in Cerecor by 47.4% in the second quarter. Northern Trust Corp now owns 55,971 shares of the company’s stock valued at $304,000 after buying an additional 17,999 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Cerecor by 294.9% in the second quarter. Bank of New York Mellon Corp now owns 57,428 shares of the company’s stock valued at $312,000 after buying an additional 42,885 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Cerecor in the second quarter valued at approximately $288,000. 57.31% of the stock is currently owned by institutional investors.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.

Featured Story: Federal Reserve

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.